Published mark
Zentalis Pharmaceuticals, Inc.
NASDAQ: ZNTL. Canonical company identity and public leadership record.
US
Record source reportedRecord not claimedNo Eval published
- Alpha ID
- alpha:company:fcfb61fc-8838-4ab6-a35a-42d6f8662edb
- SEC CIK
- 0001725160
- Record version
- vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 17, 2026
- Newest evidence
- Apr 30, 2026
- Monitoring
- Not yet monitored Details
- Integrity
- Not yet signed Methodology
- CEO
- Julie EastlandSince Apr 30, 2026
- Chair
- Not published
- Independent
- 6 / 77 directors published
- Published claims
- 243 distinct sources
- Evidence records
- 60 pinned
- Source conflicts
- 0None open
Built from 3 distinct sources and 6 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.
CorroboratedSource reportedAlpha inferenceNot disclosed
Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works
EXECUTIVE APPOINTED
Ingmar Bruns, M.D. executive of Zentalis Pharmaceuticals, Inc., effective 2026-04-30.
EffectiveEffective Apr 30, 2026E3
Monitoring
ContinuousWhat the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.
- IdentityunclaimedPublished
- Evidencesource_reportedPublished
- Evaluationnot_evaluatedPublished
- MonitoringNot yet published for this record.Not published
- AuthorityNot yet published for this record.Not published
- FreshnesscurrentPublished
Leadership
Evidence| Role | Person | Since | Status | Claim |
|---|---|---|---|---|
| Chief Medical Officer | Ingmar Bruns, M.D. | Apr 2026 | current | Source reportedE3 |
| Chief Legal Officer and Corporate Secretary | James Bucher | Apr 2026 | current | Source reportedE4 |
| President, Chief Executive Officer and Director | Julie Eastland | Apr 2026 | current | Source reportedE5 |
Board of directors
Evidence7 directors published. 6 of 7 with a published determination are independent.
| Director | Status | Since | Committees | Claim |
|---|---|---|---|---|
| David Johnson | Independent | 2020 | Compensation | Source reportedE2 |
| Enoch Kariuki, Pharm.D. | Independent | 2021 | None published | Source reportedE2 |
| Jan Skvarka, Ph.D. | Independent | 2022 | None published | Source reportedE2 |
| Julie Eastland | Not independent | 2024 | None published | Source reportedE2 |
| Karan Takhar | Independent | 2017 | CompensationCompensation; Nominating and Governance · ChairNominating and Governance, chair | Source reportedE2 |
| Luke Walker, M.D. | Independent | 2024 | Audit | Source reportedE2 |
| Scott Myers | Independent | 2024 | AuditAudit; Compensation; Nominating and GovernanceCompensationNominating and Governance | Source reportedE2 |
Committees and risk ownership
Evidence| Committee | Chair | Members | Risks assigned |
|---|---|---|---|
| Audit | Not published | Luke Walker, M.D., Scott Myers | Not described in the published record |
| Audit; Compensation; Nominating and Governance | Not published | Scott Myers | Not described in the published record |
| Compensation | Not published | David Johnson, Karan Takhar, Scott Myers | Not described in the published record |
| Compensation; Nominating and Governance · Chair | Not published | Karan Takhar | Not described in the published record |
| Nominating and Governance | Karan Takhar | Karan Takhar, Scott Myers | Not described in the published record |
Committee RecordAudit: Chair not stated; Members Luke Walker, M.D.; Scott Myers
Committee AppointmentLuke Walker, M.D.: member, Audit
Committee AppointmentScott Myers: member, Audit
Committee RecordCompensation: Chair not stated; Members David Johnson; Karan Takhar; Scott Myers
Committee AppointmentDavid Johnson: member, Compensation
Committee AppointmentKaran Takhar: member, Compensation
Committee AppointmentScott Myers: member, Compensation
Committee RecordNominating and Governance: Chair Karan Takhar; Members Karan Takhar (Chair); Scott Myers
Committee AppointmentKaran Takhar: chair, Nominating and Governance
Committee AppointmentScott Myers: member, Nominating and Governance
Control and voting power
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Authority to act
Evidence and agent registryWho can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.
Principal executive officerJulie Eastland, President, Chief Executive Officer and Director, from Apr 30, 2026
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
Financials and market context
EvidenceSecurity ListingZNTL (NASDAQ)
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 17, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.
Governance and policies
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Risk, audit, and cyber
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
AI oversight and accountability
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Legal and regulatory
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Compensation
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Other published claims
EvidencePublished Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.
Legal NameZentalis Pharmaceuticals, Inc.
Entity StatusPublic listing published
Published FactUS
Not yet in this record
CoverageA gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.
- Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
- FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
- CompensationNot reviewed. Pay design shows how incentives are governed.
- GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
- AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
- LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
- RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
- CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
- Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.
Linked people
Same claims as person records- Ingmar Bruns, M.D.Chief Medical Officercompany:fcfb61fc-8838-4ab6-a35a-42d6f8662edb:leadership_role:12
- James BucherChief Legal Officer and Corporate Secretarycompany:fcfb61fc-8838-4ab6-a35a-42d6f8662edb:leadership_role:13
- Julie EastlandPresident, Chief Executive Officer and Directorcompany:fcfb61fc-8838-4ab6-a35a-42d6f8662edb:leadership_role:14, company:fcfb61fc-8838-4ab6-a35a-42d6f8662edb:leadership_role:8
- David JohnsonDirectorcompany:fcfb61fc-8838-4ab6-a35a-42d6f8662edb:leadership_role:5
- Enoch Kariuki, Pharm.D.Directorcompany:fcfb61fc-8838-4ab6-a35a-42d6f8662edb:leadership_role:6
- Jan Skvarka, Ph.D.Directorcompany:fcfb61fc-8838-4ab6-a35a-42d6f8662edb:leadership_role:7
- Karan TakharDirectorcompany:fcfb61fc-8838-4ab6-a35a-42d6f8662edb:leadership_role:9
- Luke Walker, M.D.Directorcompany:fcfb61fc-8838-4ab6-a35a-42d6f8662edb:leadership_role:10
- Scott MyersDirectorcompany:fcfb61fc-8838-4ab6-a35a-42d6f8662edb:leadership_role:11
Subject and corrections
Public-role doctrineThis record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.
- Basis
- Published company record built from public sources
- Sources
- 6 evidence records cited. 0 with redistribution rights.
- Never published
- Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
- Record claimed
- No
- Open disputes
- 0
- Identity ownership
- unclaimed
Claiming not yet available
If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.
Evidence
Authority and rights- E1Alpha canonical company public projection. canonical identity. Retrieved Oct 17, 2026. Cited by 4 Claims.
- E2sec proxy. Published Apr 30, 2025. Retrieved Apr 28, 2026. Cited by 7 Claims.
- E3sec filing. Published Apr 30, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
- E4sec filing. Published Apr 30, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
- E5sec filing. Published Apr 30, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
- E6board_seats. board seats. Cited by 10 Claims.
What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 17, 2026- Ingmar Bruns, M.D. executive of Zentalis Pharmaceuticals, Inc., effective 2026-04-30.
- James Bucher executive of Zentalis Pharmaceuticals, Inc., effective 2026-04-30.
- Julie Eastland executive of Zentalis Pharmaceuticals, Inc., effective 2026-04-30.
- Julie Eastland seat on Zentalis Pharmaceuticals, Inc., effective 2024-01-01.
- Luke Walker, M.D. seat on Zentalis Pharmaceuticals, Inc., effective 2024-01-01.
- Scott Myers seat on Zentalis Pharmaceuticals, Inc., effective 2024-01-01.
- Luke Walker, M.D. member of Audit, effective 2024-01-01.
- Audit; Compensation; Nominating and Governance committee of Zentalis Pharmaceuticals, Inc., effective 2024-01-01.
- Scott Myers member of Audit; Compensation; Nominating and Governance, effective 2024-01-01.
- Jan Skvarka, Ph.D. seat on Zentalis Pharmaceuticals, Inc., effective 2022-01-01.
- Enoch Kariuki, Pharm.D. seat on Zentalis Pharmaceuticals, Inc., effective 2021-01-01.
- David Johnson seat on Zentalis Pharmaceuticals, Inc., effective 2020-01-01.
- David Johnson member of Compensation, effective 2020-01-01.
- Karan Takhar seat on Zentalis Pharmaceuticals, Inc., effective 2017-01-01.
- Compensation; Nominating and Governance · Chair committee of Zentalis Pharmaceuticals, Inc., effective 2017-01-01.
- Karan Takhar member of Compensation; Nominating and Governance · Chair, effective 2017-01-01.